Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.
The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.
VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.
Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.
Phase Genomics, Inc. is a biotechnology company founded in 2015 and located in Seattle, Washington. The company specializes in advanced genomic technologies, particularly ProxiMeta Hi-C genome assembly and metagenome deconvolution. Its mission is to assist scientists in making significant discoveries by delivering highly complete and accurate genomes and metagenomes. Through its innovative approaches, Phase Genomics aims to enhance the understanding of complex biological systems, facilitating research in various fields of life sciences.
Cardea Bio, Inc. is a biotechnology company based in San Diego, California, specializing in bioelectronics and graphene-based digital biosensor technology. Founded in 2013, the company develops products that facilitate precision healthcare by enhancing the ease, speed, and cost-effectiveness of diagnostics. Its key offerings include AGILE R100, an innovative assay for small molecule drug discovery, and AGILE R200, an automated high-throughput screening solution. Cardea's biosensors utilize biocompatible graphene to transform biological signals into digital data, enabling real-time analysis of biomolecules. This technology supports applications in small molecule validation, antibody characterization, and biomolecular analysis, serving the life sciences and healthcare sectors. The company also sells its products online, contributing to advancements in research and diagnostics.
Yemaachi Biotechnology uses cutting-edge immunogenomics, bioinformatics, and artificial intelligence to accelerate the development of cancer detection and cure strategies for lowering the economic burden of cancer.
Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.
Operator of a biopharmaceutical company intended to develop vaccines against infectious diseases. The company offers an end-to-end outsourcing opportunity that includes QC assays, batch records, a full set of documentation and in-person training that helps in contract manufacturing and development services and also provides a fully equipped quality control lab for identity, potency, purity and stability testing, enabling clients to overcome health inequalities and empower people to live healthy lives.
Developer of a pioneering extended durability mRNA (messenger ribonucleic acid) therapeutics, designed to transform ribonucleic acid drug development into a programmable processor. The company's innovative pipeline is dedicated to tackling unmet medical needs in the realms of metabolic, endocrinologic, and infectious diseases by the utilization of proprietary high-throughput AI (Artificial intelligence)-enabled screening platforms, strategically employed to enhance the stability and facilitate its targeted and selective delivery, enabling scientists to have fully-programmable ribonucleic acid molecules with superior durability and specificity.
Ilara Health, founded in 2018 and headquartered in Nairobi, Kenya, focuses on improving healthcare access in peri-urban and rural areas by providing AI-powered diagnostic devices. The company develops miniature diagnostic tools that integrate with a proprietary technology platform, allowing primary care doctors to deliver accurate and affordable diagnostics. By leveraging existing healthcare infrastructure, Ilara Health enables healthcare providers to record patient data through an electronic medical record system, enhancing the accessibility and reliability of diagnostic services. The company aims to transform primary care in underserved regions by making essential healthcare services more efficient and effective.
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.
Sapient enables the discovery of circulating biomarkers at unprecedented speed and scale. Their platform combines advanced mass spectrometry technologies, computational learning, and the world’s largest proprietary human chemical database to deliver actionable insights that accelerate drug creation. Their methods reduce the time and complexity of biomarker discovery at any phase, helping sponsors select and optimize the best drug candidates for clinical advancement.
E25Bio specializes in the development of rapid diagnostic tests for epidemic fever viruses. It is dedicated to preventing severe downstream health outcomes with the use of mobile, fast, real-time reporting to create unprecedented large datasets to guide informed and timely responses for the control of disease spread.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Dynavax Technologies Corporation is a biopharmaceutical company headquartered in Emeryville, California, specializing in the discovery and development of novel vaccines and treatments for infectious diseases. The company markets HEPLISAV-B, an adjuvanted vaccine for the prevention of hepatitis B infection in adults. Dynavax utilizes its unique Toll-like Receptor Immune Modulation Platform to stimulate the body's immune responses, which is integral to its product development. In addition to its commercial offerings, Dynavax has an active immuno-oncology portfolio, featuring candidates such as SD-101 and DV281. The company is engaged in various research collaborations aimed at developing COVID-19 vaccines, partnering with organizations like Clover Biopharmaceuticals, the University of Queensland, and CEPI. These partnerships reflect Dynavax's commitment to addressing urgent health challenges through innovative vaccine solutions. Founded in 1996, Dynavax has evolved from its original name, Double Helix Corporation, to focus on enhancing immune responses for better disease prevention and treatment.
A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health.
Montreal Heart Institute is a specialty hospital dedicated to the development of cardiology.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.
VisualDx is an award-winning diagnostic clinical decision support system designed to enhance diagnostic accuracy, aid therapeutic decisions, and improve patient safety. VisualDx combines the world's best curated medical image library with a powerful search engine to give clinicians patient-specific answers in seconds. VisualDx is used by more than 2,300 hospitals, clinics and medical schools around the world.
1mg is a digital consumer healthcare platform based in Gurgaon, Haryana, India, launched in 2015. It aims to make healthcare more accessible, understandable, and affordable for users. The platform allows individuals to find detailed information about medicines prescribed by doctors and purchase them directly. Users can search for medications based on ailments, drug classes, companies, and brands. Additionally, 1mg features a doctor platform designed to help users locate suitable healthcare professionals for their needs. The company also offers a diagnostics service that enhances transparency and cost-effectiveness for lab tests, empowering Indian consumers and caregivers to choose the right healthcare services at competitive prices.
Landcent accelerates the fight against global infectious diseases, by developing & delivering affordable, sustainable solutions, that are safe to use at scale.
RJH Biosciences focus on development of transfection reagents and delivery agents for nucleic acids. The company distributes its products via its website and undertakes projects on new medical treatments.
BCD Bioscience, Inc. designs and develops an oligosaccharide library and a roadmap that connects precise carbohydrate structures with their functions as prebiotics and immunomodulators to develop pharmaceutical and food ingredients. It offers a platform for creating and commercializing novel prebiotics, synbiotics, and immuno- modularity therapies for human and animal health. BCD Bioscience, Inc. was formerly known as Calyxo Biosystems, Inc. and changed its name to BCD Bioscience, Inc. in November 2019. The company was incorporated in 2019 and is based in Davis, California.
PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, founded in 2016. It connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its services. Users can engage with medical professionals via video calls, voice calls, and chat, facilitating real-time online consultations. The platform also allows patients to order laboratory tests that can be conducted at home and helps them locate nearby hospitals and clinics. Additionally, HaloDoc provides access to licensed medical laboratory services and a medical delivery service known as ApotikAntar, further enhancing the convenience and accessibility of healthcare for its users.
Biological Dynamics Inc. is an early-stage company based in San Diego, California, that focuses on developing a proprietary technology platform utilizing AC Electrokinetic technology for the direct and selective capture of large necrotic particles from physiological solutions, including whole blood, serum, and plasma. This innovative platform allows for the rapid extraction of large molecular weight particles that would not naturally settle. The company offers a range of diagnostic solutions, including the TR(ACE) Assay for monitoring treatment response and tumor burden across various cancers, as well as liquid biopsy testing for personalized medicine applications. Additionally, Biological Dynamics provides clinical laboratory services that encompass molecular and next-generation sequencing. Their technology supports various medical needs, including autoimmune disorders, transplant rejection, infectious diseases, and brain injuries, while also aiding in drug development for conditions like Alzheimer's disease. Founded in 2008, Biological Dynamics aims to enhance disease detection and intervention, ultimately improving patient outcomes and reducing healthcare costs.
Qloudlab specializes in innovative healthcare solutions, particularly through its development of Sceptre, the world's first touchscreen-based biosensor. This modular platform facilitates a wide range of diagnostic tests, including blood, urine, saliva, and skin analyses, all within a single mobile system. By integrating smartphone technology with healthcare and cloud computing, Qloudlab aims to streamline diagnostics at the Point-of-Care, making testing more accessible and efficient. The company's technology is designed to be cost-effective, enhancing the user experience for both patients and healthcare professionals. Through its advancements, Qloudlab is positioned to transform the diagnostics landscape, ensuring that essential health information is readily available and easily obtainable.
Phase Genomics, Inc. is a biotechnology company founded in 2015 and located in Seattle, Washington. The company specializes in advanced genomic technologies, particularly ProxiMeta Hi-C genome assembly and metagenome deconvolution. Its mission is to assist scientists in making significant discoveries by delivering highly complete and accurate genomes and metagenomes. Through its innovative approaches, Phase Genomics aims to enhance the understanding of complex biological systems, facilitating research in various fields of life sciences.
Butterfly Network designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. Jonathan M. Rothberg, Nevada Sanchez, and Tyler S. Ralston founded it in 2011, with its headquarters in Guilford in Connecticut.
Evolve Biosystems, Inc. is a biotechnology company based in Davis, California, that focuses on developing probiotic-based biotherapeutics aimed at establishing, restoring, and maintaining a healthy human microbiome. The company specializes in addressing gut dysbiosis across all stages of life, with particular emphasis on supporting the microbiome of newborn infants. Evolve Biosystems offers both consumer-directed home use products and hospital-based solutions for neonatal intensive care units. With a discovery platform that also addresses microbiome issues in production animals, the company aims to meet various unmet clinical needs. Founded in 2011, Evolve Biosystems is committed to advancing microbiome health through innovative probiotic solutions.
NemoCare is developing the smartest and most comprehensive patient monitoring and management system. It is an innovative, continuous vital sign data acquisition, analysis and prediction engine that combines unobtrusive wireless wearable sensors and networks, analytical algorithms and big data to provide affordable continuous, high resolution monitoring for all newborns in hospital, and at home. We use design thinking principles to build life-saving technologies that will transform the way healthcare is delivered. Our current area of work is in newborn and maternal care.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Qloudlab specializes in innovative healthcare solutions, particularly through its development of Sceptre, the world's first touchscreen-based biosensor. This modular platform facilitates a wide range of diagnostic tests, including blood, urine, saliva, and skin analyses, all within a single mobile system. By integrating smartphone technology with healthcare and cloud computing, Qloudlab aims to streamline diagnostics at the Point-of-Care, making testing more accessible and efficient. The company's technology is designed to be cost-effective, enhancing the user experience for both patients and healthcare professionals. Through its advancements, Qloudlab is positioned to transform the diagnostics landscape, ensuring that essential health information is readily available and easily obtainable.
Danforth Technology Company (DTC) is a venture builder based in St. Louis, Missouri, and operates as a subsidiary of the Donald Danforth Plant Science Center. Its primary role is to facilitate the early-stage development of startup companies that leverage technologies developed by the Center's scientists. DTC focuses on moving scientific discoveries into the marketplace more efficiently by providing intellectual property development, licensing, and entrepreneurship support. The company also offers seed funding and early management assistance to promising startups, enhancing the potential for innovation in plant science and contributing to broader societal goals such as improving human health and environmental sustainability.
Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic diseases that require long-term treatment. The company is known for its innovative Medici Drug Delivery System, which utilizes subcutaneous delivery methods to provide steady dosing of therapeutic agents, particularly for conditions such as type 2 diabetes and obesity. Its flagship product, ITCA 650, is currently in a phase 3 clinical program aimed at improving treatment outcomes for diabetes patients through a unique delivery mechanism. In addition to diabetes, Intarcia is engaged in research and development for therapies targeting autoimmune disorders and other chronic conditions. Founded in 1995 and headquartered in Boston, Massachusetts, Intarcia also has a manufacturing facility in Hayward, California, and a research center in Durham, North Carolina.
Mologic Ltd. is a diagnostic product developer based in Thurleigh, United Kingdom, founded in 2003. The company specializes in creating innovative solutions for the research market, focusing on areas such as clinical research, diagnostic development, and microbial physiology. Mologic offers a range of products, including lateral flow kits for human Alpha-1 antitrypsin, desmosine ELISA kits for urine assays, and the fMLP assay kit for measuring fMLP in human urine. In addition to its product lineup, Mologic provides services such as assay and reagent development, clinical evaluation studies, and the creation of high-performance antibodies targeting challenging biological entities. The company was established by Paul and Mark Davis, driven by a mission to enhance healthcare and education, thereby improving patient care and quality of life.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive patient monitoring products. It provides a patient monitoring solution that incorporates a monitor or circuit board and sensors, including both proprietary single-patient use and reusable sensors and cables. The company also offers Masimo Signal Extraction Technology, which provides the capabilities of measure-through motion and low perfusion pulse oximetry to address the primary limitations of conventional pulse oximetry. In addition, it provides remote-alarm/monitoring solutions and software. The company sells its products to end-users through direct sales force and distributors, as well as to original equipment manufacturers and partners to incorporate into their products. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Atomo Diagnostics is an Australian company that specializes in the research, design, development, and manufacturing of medical devices for blood-based rapid testing, applicable for both professional use and self-testing. Founded in 2010 and headquartered in Leichhardt, Australia, the company provides the AtomoRapid RDT platform, which supports various blood-based lateral flow test assays. These devices are utilized in screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics focuses on enhancing usability, safety, and accuracy in rapid diagnostic testing by integrating all test components into a streamlined solution, thereby reducing user error rates. The company operates internationally, with a presence in Europe, Asia, Africa, and Central and South America, and is led by a team experienced in commercializing innovative healthcare products. Its commitment to improving user experience distinguishes Atomo Diagnostics in the point-of-care testing market.
Ceres Nanosciences, Inc. is a privately held life sciences company based in Manassas, Virginia, specializing in the research, development, and commercialization of sample preparation products and diagnostic tests. Utilizing its proprietary Nanotrap technology, Ceres captures, enriches, and preserves biomarkers, facilitating the early detection of various diseases, including cancer, cardiac conditions, and infectious diseases. The company's offerings include a toolset designed for the enrichment of low abundance biomarkers found in complex biofluids such as serum, plasma, urine, and saliva. Among its products is the Nanotrap Lyme Antigen Test, which directly measures Lyme antigens in urine using a Western Blot format. Ceres is funded through federal agency grants and industry collaborations, and it aims to enhance patient outcomes while reducing healthcare costs through innovative diagnostic solutions.
Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU is the kind of place where the big news doesn't always involve sports, politics, fashion or even weather. The big news is always about health — health care, health education, health-related research. And various organizations and publications that rank American institutions, programs and faculty in a variety of categories have taken note. Nearly one million patient visits each year. Educating thousands of future health care providers. You get the picture. Immerse yourself in more facts and stats than you probably need about Portland's largest employer, Oregon's provider of care to every corner of the state, and one of the nation's top 28 biomedical research institutions. Oregon Health & Science University is the state’s only academic health center. It provides an uncommon array of services from providing the state’s most comprehensive health care, to educating the next generation of clinicians and biomedical researchers, to achieving breakthroughs and innovations.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions.
SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
IDRI is a Seattle-based not-for-profit committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, we strive to create an efficient pathway to bring scientific innovation from the lab to the people who need it most.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
Zyomyx has a unique expertise in and passion for tackling difficult “outside-the-box” problems. Highly user-friendly, instrument-free point-of-care tests need to be designed with an advanced level of cartridge engineering and reagent stability, and aligned with aggressive cost targets. Zyomyx specializes in exactly these demanding product requirements. Our immediate focus is an advanced, but simple to use and inexpensive CD4 T-cell point-of-care test that will be launched globally and configured to especially meet the demanding specifications for use in low and middle income countries.
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.
YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.